In Segment A, individuals will acquire various doses and schedules of oral ABBV-744 tablet to establish Risk-free dosing program. Extra individuals are going to be enrolled on the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "include-on" therapy. In https://abbv-744-brd4-inhibition79023.bloggactivo.com/31479262/abbv-744-in-combination-with-immunotherapy-an-overview